Viking Therapeutics Stock (NASDAQ:VKTX)
Previous Close
$62.81
52W Range
$8.28 - $99.41
50D Avg
$57.42
200D Avg
$51.16
Market Cap
$7.39B
Avg Vol (3M)
$3.88M
Beta
1.00
Div Yield
-
VKTX Company Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| PTCT | PTC Therapeutics, Inc. |
| CWBR | CohBar, Inc. |
| MREO | Mereo BioPharma Group plc |
| DAWN | Day One Biopharmaceuticals, Inc. |
| SRPT | Sarepta Therapeutics, Inc. |
| MCRB | Seres Therapeutics, Inc. |
| AVRO | AVROBIO, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| AXSM | Axsome Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| OCEA | Ocean Biomedical, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| ELEV | Elevation Oncology, Inc. |
| ENVB | Enveric Biosciences, Inc. |